2.1
Nivolumab (Opdivo, Bristol-Myers Squibb) as monotherapy is indicated for the treatment of locally advanced, unresectable or metastatic urothelial carcinoma in adults after failure of platinum-containing therapy.
2 Information about nivolumab
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics.
Price
2.3
The cost of nivolumab is £439 per 40‑mg vial or £1,097 per 100‑mg vial (excluding VAT; BNF online accessed September 2017).
2.4
The company has a commercial arrangement, which would have applied if the technology had been recommended.